Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Bio Medica Laboratories Ltd (BMLL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BMLL Pharmaceuticals & Drugs | Small Cap | Bio Medica Labs. Share Price
BSE Share Price
Not Listed
Not Listed
Bio Medica Laboratories Ltd (BMLL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BMLL Pharmaceuticals & Drugs | Small Cap | Bio Medica Labs. Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹183 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹9.4
TTM Sales
₹43.1 Cr.
Book Value per Share
₹23.8
P/E Ratio
15.52
Lower than its 5-year historical median
Industry PE
54.1
Price to Book (P/B)
6.11
Lower than its 5-year historical median
Price to Sales (P/S)
4.24
Lower than its 5-year historical median
EV/EBITDA
11.13
In line with its 5-year historical median
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
57.64%
Return on Capital Employed (ROCE)
39.14%
Return on Assets (ROA)
21.33%
Operating Profit Margin
46.4%
Net Profit Margin
27.59%
Gross Profit Margin
40.4%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-0.05%
Operating Profit Growth (1 Year)
-
28.9%
Net Profit Growth (1 Year)
-
22.58%
Asset Quality
Promoter Holding
67.70%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹17 Cr.
Equity
₹12.6 Cr.
Face Value
₹10
All Time Low / High
₹0.00 / 0.00
Check Before You Invest
Quality
Locked
Login to view analysis.
Valuation
Locked
Login to view analysis.
Price Trend
Locked
Login to view analysis.
Is Bio Medica Laboratories Ltd a good quality company?
Bio Medica Laboratories Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Bio Medica Laboratories Ltd performance compare with that of its Peers?
Revenue growth of Bio Medica Laboratories Ltd vs industry peers?
Bio Medica Laboratories Ltd revenue CAGR is 24.52%, compared to the industry median CAGR of %, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Bio Medica Laboratories Ltd?
Promoters hold 67.70% of the Bio Medica Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Valuation ratios of Bio Medica Laboratories Ltd vs historical?
The current P/E ratio of 15.52 is higher than its historical median of , indicating that the stock is trading above its historical average valuation.
10 Year X-Ray : Login to view analysis.
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bio Medica Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 10.2% | 33.6% | 64.2% | 45.3% | - |
| Value Creation Index ⓘ | -0.3 | 1.4 | 3.6 | 2.2 | - |
Growth Parameters ⓘ |
|||||
| Sales ⓘ | 16.2 | 15.3 | 38.3 | 38.3 | 38 |
| Sales YoY Gr. | - | -6% | 151.3% | -0.1% | - |
| Adj EPS ⓘ | 0.4 | 2.7 | 10.6 | 12.7 | 9.3 |
| YoY Gr. | - | 655.6% | 288.6% | 20.4% | - |
| BVPS (₹) ⓘ | 2.7 | 5.4 | 16.1 | 28.8 | 23.7 |
| Adj Net Profit ⓘ | 0.3 | 2.5 | 9.7 | 11.7 | 12 |
| Cash Flow from Ops. ⓘ | 2.3 | 1.6 | -4.6 | -5.8 | - |
| Debt/CF from Ops. ⓘ | 4.2 | 6.5 | -3.3 | -4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 33.1% | -0.1% | ||||
| Adj EPS ⓘ | NA | NA | 228.2% | 20.4% | ||||
| BVPSⓘ | NA | NA | 121.1% | 79.2% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 13.7 | 67.7 | 98.6 | 56.8 | 35.4 |
| Op. Profit Mgn % ⓘ | 10.5 | 36.9 | 40.4 | 48.9 | NAN |
| Net Profit Mgn % ⓘ | 2.1 | 16.4 | 25.3 | 30.5 | 30.5 |
| Debt to Equity ⓘ | 3.9 | 2.1 | 1 | 0.9 | - |
| Working Cap Days ⓘ | 0 | 238 | 198 | 386 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 103 | 103 | 248 | 0 |
Valuation of Bio Medica Labs. - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Sales | 38 | 43 |
| Operating Expenses ⓘ + | 23 | 23 |
| Operating Profit ⓘ | 15 | 20 |
| Operating Profit Margin (%) | 40.4% | 46.4% |
| Other Income ⓘ + | 0 | 0 |
| Interest ⓘ | 1 | 3 |
| Depreciation ⓘ | 1 | 1 |
| Profit Before Tax ⓘ | 13 | 16 |
| Tax ⓘ | 3 | 4 |
| Profit After Tax | 10 | 12 |
| PAT Margin (%) | 25.3% | 27.6% |
| Adjusted EPS (₹) | 10.6 | 12.8 |
| Dividend Payout Ratio (%) | 0% | 0% |
| PARTICULARS | Mar'25 | Mar'26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 15 | 27 | |||||||||
| Debt + | 13 | 37 | |||||||||
| Minority Interest | 0 | -6 | |||||||||
| Trade Payables | 4 | 6 | |||||||||
| Others Liabilities ⓘ | 6 | 10 | |||||||||
| Total Liabilities ⓘ | 39 | 73 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 8 | 17 | |||||||||
| CWIP ⓘ | 0 | 0 | |||||||||
| Investments ⓘ | 0 | 0 | |||||||||
| Inventories | 18 | 36 | |||||||||
| Trade Receivables | 4 | 11 | |||||||||
| Cash Equivalents | 0 | 0 | |||||||||
| Others Assets ⓘ | 9 | 8 | |||||||||
| Total Assets ⓘ | 39 | 73 | |||||||||
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -5 | -6 |
| Cash Flow From Investing Activity ⓘ + | 0 | -2 |
| Cash Flow From Financing Activity ⓘ + | 5 | 8 |
| Net Cash Flow ⓘ | -0 | 0 |
| PARTICULARS | Mar'25 | Mar'26 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 65.87 | 57.64 | ||||||||
| ROCE (%) | 48.73 | 39.14 | ||||||||
| Asset Turnover Ratio | 1 | 0.77 | ||||||||
| PAT to CFO Conversion(x) | -0.5 | -0.5 | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 39.10 | 63.30 | ||||||||
| Inventory Days | 172.80 | 230.90 | ||||||||
| Payable Days | 159.80 | 181.10 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Annual reports
No annual reports available.
Concalls
No concalls available.
Bio Medica Laboratories Ltd FAQs
The current trading price of Bio Medica Labs. on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Bio Medica Labs. stood at ₹182.8 Cr
The latest P/E ratio of Bio Medica Labs. as of 31-Dec-1969 is 15.66.
The latest P/B ratio of Bio Medica Labs. as of 31-Dec-1969 is 6.13.
The 52-week high of Bio Medica Labs. is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bio Medica Labs. is ₹38.30 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bio Medica Laboratories Ltd is a below average quality company.
The key valuation ratios of Bio Medica Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bio Medica Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Bio Medica Laboratories Ltd
Bio Medica Laboratories was originally incorporated as a private limited company with the name of ‘Bio Medica Laboratories Private Limited’ under the Companies Act, 2013 vide certificate of incorporation dated August 14, 2015, issued by Registrar of Companies, Gwalior. Further, the company was converted into a Public Limited Company in pursuance of a special resolution passed by the members of the Company at the Extra- Ordinary General Meeting held on September 09, 2024 & name of the company changed from ‘Bio Medica Laboratories Private Limited’ to ‘Bio Medica Laboratories Limited’ & Registrar of Companies, CPC has issued a new certificate of incorporation consequent upon conversion dated October 24, 2024.
Bio Medica Laboratories is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The company operates on a B2B business model through contract manufacturing and does not deal directly with the end users. The company manufactures formulations for various companies according to their specific requirements and specifications for the type of formulation needed. Additionally, it enters into agreements with them, allowing their name and address to be displayed on the packaging as ‘Technical Collaborator’ or ‘marketed by’ alongside the company’s name as the manufacturer.
The company holds Good Manufacturing Practices (GMP) certificate issued by Food & Drugs Administration, Madhya Pradesh, for complying with established GMP standards and guidelines. The company maintain stringent quality control standards throughout the entire manufacturing process.
Business area of the company
Bio Medica Laboratories is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences.
Products of the company
Liquid injectables
- 100ml Amikacin Sulphate IP injection
- Vitamin B12, D3 & Calcium Gluconolactobionate injection
- 2ml Amikacin Sulphate injection
- Buprenorphine injection
- 30ml Amikacin Sulphate injection
Dry Powder Injectables
- Piperacillin & Tazobactam injection
- Ceftrixone & Sulbactam for injection
- Meropenem injection
- Ceftriaxone injection
- Artesunate injection
History and milestones
- 2015: Incorporation of Company.
- 2024: Alteration of Name clause of Memorandum of Association and subsequently Conversion of the Company from Private Limited Company into Public Limited Company.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now